infigratinib infigratinib infigratinib, sold under the brand name truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer). infigratinibclinical datatrade namestruseltiqother namesbgj-398license data us dailymed: infigratinib pregnancycategory au: d routes ofadministrationby mouthdrug classtyrosine kinase inhibitoratc codel01en03 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only us: ℞-only identifierscas number872511-34-7pubchem cid53235510drugbankdb11886chemspider26333103uniia4055me1vkkeggd11589comptox dashboard (epa)dtxsid70236238 chemical and physical dataformulac26h31cl2n7o3molar mass560.48 g·mol−13d model (jsmol)interactive image smiles ccn1ccn(c2ccc(nc3cc(n(c)c(=o)nc4c(cl)c(oc)cc(oc)c4cl)ncn3)cc2)cc1 inchi inchi=1s/c26h31cl2n7o3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16h,5,10-13h2,1-4h3,(h,32,36)(h,29,30,31)key:qadpyrihxkwusv-uhfffaoysa-n infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors fgfr1, fgfr2 and fgfr3 it was designated an orphan drug by the us food and drug administration (fda) in 2019, and it was approved for medical use in the united states in may 2021. medical uses infigratinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test.